0001326190false00013261902024-11-152024-11-15

​

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 15, 2024

ALTIMMUNE, INC.

(Exact name of registrant as specified in its charter)

​

​

​

​

​

​

Delaware

 

001-32587

 

20-2726770

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

​

​

​

​

​

910 Clopper Road, Suite 201S

Gaithersburg, Maryland

​

​

​

20878

(Address of principal executive offices)

​

​

​

(Zip Code)

​

Registrant’s telephone number including area code: (240) 654-1450

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

​

​

​

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Securities registered pursuant to Section 12(b) of the Act:

​

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common stock, par value $0.0001 per share

ALT

The NASDAQ Global Market

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

​

​

​

​

​

​

Item 8.01 Other Events

On November 15, 2024, Altimmune, Inc. presented data from its 12-week Phase 1b trial of pemvidutide in metabolic dysfunction-associated steatotic liver disease (MASLD) at The Liver Meeting® of the American Association for the Study of Liver Diseases.

The data were derived from an analysis of plasma samples from subjects who completed a randomized placebo-controlled Phase 1b trial of pemvidutide in subjects with overweight or obesity and MASLD. In the Phase 1b clinical trial, 94 subjects with obesity or overweight and liver fat content (LFC) greater than or equal to 10% were dosed 1:1:1:1 to pemvidutide (1.2mg, 1.8mg and 2.4mg) or placebo administered once-weekly subcutaneously for 12 weeks. In this study, pemvidutide reduced LFC relative to baseline by up to 68.5% and decreased total cholesterol and triglycerides by up to 12.2% and 44.6%, respectively, after 12 weeks of treatment.

​

​

​

​

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​

​

​

​

​

​

ALTIMMUNE, INC.

​

​

​

​

​

By:

 

/s/ Gregory Weaver

​

​

 

Name: Gregory Weaver

​

​

 

Title: Chief Financial Officer

​

Dated: December 11, 2024

​

v3.24.3
Document and Entity Information
Nov. 15, 2024
Cover [Abstract]  
Document Type 8-K
Document Period End Date Nov. 15, 2024
Entity File Number 001-32587
Entity Registrant Name ALTIMMUNE, INC.
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 20-2726770
Entity Address State Or Province MD
Entity Address, Address Line One 910 Clopper Road
Entity Address, Adress Line Two Suite 201S
Entity Address, City or Town Gaithersburg
Entity Address, Postal Zip Code 20878
City Area Code 240
Local Phone Number 654-1450
Title of 12(b) Security Common stock, par value $0.0001 per share
Trading Symbol ALT
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001326190
Amendment Flag false
Pre-commencement Issuer Tender Offer false
Pre-commencement Tender Offer false
Soliciting Material false
Written Communications false
v3.24.3
Document Information
Nov. 15, 2024
Cover [Abstract]  
Document Type 8-K
Amendment false
CIK 0001326190
Registrant Name ALTIMMUNE, INC.
Period End Date Nov. 15, 2024
Altimmune (NASDAQ:ALT)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more Altimmune Charts.
Altimmune (NASDAQ:ALT)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more Altimmune Charts.